Jefferies resumed coverage on Viatris with a new price target
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies resumed coverage of Viatris with a rating of Hold and set a new price target of $11.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2025 | $10.00 | Neutral | Goldman |
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
| 4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
| 2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/27/2023 | $13.00 → $15.00 | Hold → Buy | Jefferies |
| 11/10/2022 | $9.00 → $12.00 | Sell → Neutral | UBS |
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)